LexDanaLexDanabeta
Inventor

Patrick L. Iversen

Inventor
Corvallis, OR, US

Overview

95→
Patents
1995–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 95 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary
C12NMicroorganisms or enzymes27%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
A61KPreparations for medical, dental or toiletry purposes21%
C07KPeptides8%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium6%
Y02ATechnologies for adaptation to climate change4%
C07HSugars3%
C07DHeterocyclic compounds2%
C08FMacromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds2%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%
PatentTitleYear
11,072,793DsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups202110,905,782Compositions for enhancing transport of molecules into cells202110,626,396Antisense composition and method for treating muscle atrophy202010,538,769Renal selective inhibition of cytochrome P450 3A5202010,533,174Splice-region antisense composition and method202010,479,996Antisense antiviral compound and method for treating ss/RNA viral infection201910,300,149Compositions for enhancing transport of molecules into cells201910,144,762Antibacterial antisense oligonucleotide and method201810,100,305Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites201810,017,763dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups201810,006,031Antisense composition and method for treating muscle atrophy20189,982,261Antisense antiviral compounds and methods for treating a filovirus infection20189,572,899'Compositions for enhancing transport of molecules into cells'20179,534,220'Antisense antibacterial method and compound'20179,499,583'Antibacterial antisense oligonucleotide and method'20169,487,784'Antisense antibacterial method and compound'20169,487,786'Immunosuppression compound and treatment method'20169,416,361'Splice-region antisense composition and method'20169,394,323'Antisense antiviral compound and method for treating influenza viral infection'20169,382,536'Antisense antiviral compounds and methods for treating a filovirus infection'20169,347,063'Oligonucleotide analog and method for treating flavivirus infections'20169,249,243'Antibacterial antisense oligonucleotide and method'20169,238,042'Antisense modulation of interleukins 17 and 23 signaling'20169,068,185'Antisense modulation of nuclear hormone receptors'20158,933,216'Immunosuppression compound and treatment method'20158,906,872'Antisense antiviral compound and method for treating ssRNA viral infection'20148,895,722'Splice-region antisense composition and method'20148,877,725'Peptide conjugated, inosine-substituted antisense oligomer compound and method'20148,785,407'Antisense antiviral agent and method for treating ssRNA viral infection'20148,785,410'Antisense composition and method for treating muscle atrophy'20148,759,307'Oligonucleotide compound and method for treating nidovirus infections'20148,703,735'Antisense antiviral compounds and methods for treating a filovirus infection'20148,697,858'Antisense antiviral compound and method for treating influenza viral infection'20148,618,270'Oligonucleotide analog and method for treating flavivirus infections'20138,592,386'Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis'20138,536,147'Antibacterial antisense oligonucleotide and method'20138,524,684'Antisense antiviral compounds and methods for treating a filovirus infection'20138,524,676'Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds'20138,501,704'Immunosuppression compound and treatment method'20138,436,163'Splice-region antisense composition and method'20138,415,313'Antisense oligomers and methods for inducing immune tolerance and immunosuppression'20138,357,664'Antisense antiviral compound and method for treating influenza viral infection'20138,329,668'Antisense antiviral compound and method for treating picornavirus infection'20128,314,072'Antisense antibacterial method and compound'20128,198,429'Antisense antiviral compounds and methods for treating a filovirus infection'20128,168,604'Antisense antiviral compounds and methods for treating a filovirus infection'20128,129,352'Antisense antiviral compound and method for treating ssRNA viral infection'20128,084,433'Antisense antiviral compound and method for treating ssRNA viral infection'20118,067,569'Splice-region antisense composition and method'20118,067,571'Antibacterial antisense oligonucleotide and method'20118,053,420'Peptide conjugated, inosine-substituted antisense oligomer compound and method'20118,030,291'Antisense antiviral compounds and methods for treating a filovirus infection'20118,030,292'Antisense antiviral compounds and methods for treating a filovirus infection'20118,008,469'Antisense compound for inducing immunological tolerance'20117,989,608'Immunomodulatory agents and methods of use'20117,888,012'Antisense composition and method for treating muscle atrophy'20117,855,283'Antisense antiviral compound and method for treating arenavirus infection'20107,807,801'Oligonucleotide analog and method for treating flavivirus infections'20107,790,694'Antisense antibacterial method and compound'20107,754,238'Delivery of microparticle-conjugated drugs for inhibition of stenosis'20107,625,873'Antisense antibacterial method and compound'20097,582,615'Antisense antiviral compound and method for treating arenavirus infection'20097,524,829'Antisense antiviral compounds and methods for treating a filovirus infection'20097,507,196'Antisense antiviral compounds and methods for treating a filovirus infection'20097,468,418'Compositions for enhancing transport of molecules into cells'20087,402,574'Antisense composition and method for treating cancer'20087,238,675'Antisense antibacterial method and composition'20077,198,949'Compositions and methods for altering the biodistribution of biological agents'20077,115,583'Microbubble compositions and methods for oligonucleotide delivery'20067,094,765'Antisense restenosis composition and method'20067,049,431'Antisense antibacterial cell division composition and method'20066,875,747'Antisense to c-myc for treatment of polycystic kidney disease'20056,869,795'Antisense compositions and cancer-treatment methods'20056,841,542'Transforming growth factor beta (TGF-β) blocking agent-treated stem cell composition and method'20056,828,105'Antisense antiviral agent and method for treating ssRNA viral infection'20046,784,291'Splice-region antisense composition and method'20046,764,680'Combined approach to treatment of cancer with hCG vaccines'20046,686,338'Enzyme inhibitors for metabolic redirection'20046,677,153'Antisense antibacterial method and composition'20046,673,778'Enzyme inhibitors for metabolic redirection'20046,537,814'Compositions and methods for altering the biodistribution of biological agents'20036,365,577'p53 antisense agent and method'20026,365,351'Non-invasive method for detecting target RNA'20026,245,747'Targeted site specific antisense oligodeoxynucleotide delivery method'20016,124,271'Method and conjugate for treating H. pylori infection'20006,117,858'Compositions and methods for altering the biodistribution of biological agents'20005,849,727'Compositions and methods for altering the biodistribution of biological agents'19985,741,900'Method for preparing poly (FdU).sub.n'19985,663,321'Oligonucleotide prodrugs containing 5-fluorouracil'19975,643,890'Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases'19975,641,754'Antisense oligonucleotide compositions for selectively killing cancer cells'19975,618,796'Metal binding oligonucleotide and methods and compositions for their use to treat metal toxicity'19975,614,505'Method of treating cancer with homo-oligonuleotides of 5-FU 5\'-monophosphate'19975,552,390'Phosphorothioate inhibitors of metastatic breast cancer'19965,457,187'Oligonucleotides containing 5-fluorouracil'1995

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1995–2007Patents assigned to UNIV NEBRASKA (16)· patent assignee history
1995–2001Based in Omaha, NE, US· patent location history
1997Based in Ralston, NE, US· patent location history
2000–2017Patents assigned to AVI BIOPHARMA INC (42)· patent assignee history
2000–2021Based in Corvallis, OR, US· patent location history
2011–2018Patents assigned to IVERSEN PATRICK L (28)· patent assignee history
2011–2014Patents assigned to WELLER DWIGHT D (16)· patent assignee history
2013–2021Patents assigned to SAREPTA THERAPEUTICS INC (35)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
AVI BIOPHARMA INC422000–2017
SAREPTA THERAPEUTICS INC352013–2021
IVERSEN PATRICK Lself282011–2018
UNIV NEBRASKA161995–2007
WELLER DWIGHT D162011–2014
Locations
LocationPatentsSpan
Corvallis, OR, US852000–2021
Omaha, NE, US91995–2001
Ralston, NE, US11997